Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Achieve Life Sciences (ACHV) Cash & Current Investments (2016 - 2026)

Achieve Life Sciences (ACHV) has disclosed Cash & Current Investments for 17 consecutive years, with $30.5 million as the latest value for Q1 2026.

  • Quarterly Cash & Current Investments fell 8.79% to $30.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $30.5 million through Mar 2026, down 8.79% year-over-year, with the annual reading at $36.4 million for FY2025, 5.95% up from the prior year.
  • Cash & Current Investments for Q1 2026 was $30.5 million at Achieve Life Sciences, down from $36.4 million in the prior quarter.
  • The five-year high for Cash & Current Investments was $107.9 million in Q2 2024, with the low at $12.8 million in Q1 2023.
  • Average Cash & Current Investments over 5 years is $40.1 million, with a median of $33.4 million recorded in 2025.
  • The sharpest move saw Cash & Current Investments tumbled 64.85% in 2023, then surged 420.4% in 2024.
  • Achieve Life Sciences' Cash & Current Investments stood at $22.8 million in 2022, then tumbled by 37.37% to $14.3 million in 2023, then skyrocketed by 141.09% to $34.4 million in 2024, then rose by 5.95% to $36.4 million in 2025, then dropped by 16.24% to $30.5 million in 2026.
  • Per Business Quant, the three most recent readings for ACHV's Cash & Current Investments are $30.5 million (Q1 2026), $36.4 million (Q4 2025), and $64.3 million (Q3 2025).